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Background: Fibronectin Binding Protein A (FnBPA) is an invasin from Staphylococcus aureus that allows this
pathogen to internalize into eukaryote cells. It was previously demonstrated that recombinant Lactococcus lactis
expressing FnBPA were invasive and able to transfer a plasmid to eukaryotic cells in vitro and in vivo. In this study,
the invasivity of recombinant strains of Lactococcus lactis that express FnBPA under the control of its constitutive
promoter or driven by the strong nisin inducible expression system (NICE) were studied.
Results: It was demonstrated that the nisA promoter allows an increase of FnBPA expression on the surface of
Lactococcus lactis surface, as shown by flow cytometry, which subsequently enhanced internalization and plasmid
transfer properties in vitro in Caco2 cells and Bone Marrow Dendritic Cells. In vivo, the use of nisA promoter increase
the plasmid transfer in cells of both the small and large intestine of mice.
Conclusion: FnBPA expression at the surface of recombinant L. lactis is positively correlated to internalization and
DNA transfer properties. The recombinant strains of L. lactis that expresses FnBPA under the control of the nisin
inducible expression system could thus be considered as an improved tool in the field of DNA transfer.
Keywords: FnBPA, Lactococcus lactis, nisA promoter, Caco-2 cells, BMDCs, Invasiveness, Plasmid transferBackground
DNA delivery by lactic acid bacteria (LAB) is a topic that
has been the focus of an increasing amount of research
groups, not only for its potential use for vaccination pur-
poses, but also as a mean to deliver bioactive compounds
directly in the gastrointestinal tract [1-6]. In this regard, a
promising advance has been the development of a system
based on a new vector for DNA delivery using lactococci,
named Vaccination using lactic acid bacteria or pValac [7].
This plasmid harbours an eukaryotic region containing
the CytoMegaloVirus promoter (pCMV) under which the
gene of interest can be expressed, the polyadenylation sig-
nal of Bovine growth hormone (BGH polyA) which is* Correspondence: jean-marc.chatel@jouy.inra.fr
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unless otherwise stated.required for gene expression by eukaryotic host cells, a
prokaryotic region containing the RepA/RepC replication
origins for both Escherichia coli and Lactococcus (L.) lac-
tis, and a chloramphenicol resistance gene (Cm) for bac-
teria selection. In order to allow expression of the genes of
interest by eukaryotic cells, such as those of the gastro-
intestinal tract, these DNA delivery vectors must be effect-
ively incorporated into these cells. An interesting way to
achieve this latter objective is to take advantage of the
mechanisms used by invasive pathogens.
Pathogenic bacteria can be internalized by eukaryote
cells by using invasins expressed on their cell surface [8]
such as the Fibronectin Binding Protein A (FnBPA) stem-
ming from Staphylococcus (S.) aureus [9], the Internalin A
from Listeria monocytogenesis [10,11], or the invasin of
Yersinia pseudotuberculosis [12,13]. Thus, these proteins
possess the potential to be used as tools in geneticl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 FnBPA expression at the surface of LL-pNisFnBPA and
LL-FnBPA as analyzed by flow cytometry where the secondary
antibody was labeled with FITC. Results are expressed as means ±
standard deviation. a-bMeans with a different letter are significantly
different from each other with a p≤ 0.05.
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veloped from non-pathogenic strains considered “GRAS”
(Generally Regarded As Safe) for human health, such as
the model LAB, L. lactis.
In the particular case of FnBPA, the internalization
process involves three molecules including the bacterial
FnBPA, the fibronectin synthesized by the host, and a
clustering of integrins from the host cell surface. The
binding between these three entities results in the bac-
terial uptake by the eukaryote host involving tyrosine
phosphorylation and actin rearrangement [14].
The role of FnBPA in cell internalization using L. lactis
has been previously described by Que et al. [15,16]. This
process has been used in the design of recombinant bac-
terial strains expressing FnBPA with varying results, thus
we hypothesized that an increase of the external expres-
sion of the invasin could improve the functionality of
the DNA delivery system. One method of accomplishing
this goal would be to use a strong heterologous pro-
moter such as the nisA gene promoter which has been
described as being one of the most efficient promoters
used during the last years [17,18]. The nisA promoter is
derived from the Lactococcus lactis nisin gene cluster
where nisin is considered as an outside inducer that re-
quires the control of the nisK and nisR gene regulators.
This strategy could improve current constructs and im-
prove DNA delivery in eukaryote cells.
The objectives of this work were to construct a Lacto-
coccus lactis strain expressing the FnBPA gene under the
control of the nisA promoter and evaluate if this new
construct was able to increase FnBPA expression com-
pared to the use of constitutive FnBPA promoter and
consequently improve bacterial internalization and nu-
cleic acid transfer in eukaryotic cells in vitro and in the
gastrointestinal tract of mice.
Results
pNisFnBPA plasmid design
Plasmid pNisFnBPA was obtained by placing the fnbpA
gene of S. aureus, without its constitutive promoter, but
under control of the nisA promoter (PnisA). The back-
bone of this construction is provided by the pOri253
plasmid allowing resistance to erythromicyn. The final
plasmid pNisFnBPA was used to transform the L. lactis
NZ9000 wild type strain, resulting in LL-pNisFnBPA
strain, since this strain, a derivative of L. lactis MG1363,
contains the nisRK gene necessary for the expression of
genes downstream of the nisA promoter in the presence
of sub inhibitory concentrations of nisin.
FnBPA expression characterized by FACS analysis
FnBPA expression at the surface of LL-pNisFnBPA and
LL-FnBPA was analyzed by fluorescence-activated cell
sorting (FACS) using anti-FnBPA antibody after nisininduction. An increase of FnBPA expression in the range
of 55% is observed in the strain with FnBPA expressed
under the control of nisA promoter (Figure 1), compared
to the strain with the constitutive promoter. Different
concentrations of nisin were used for induction (0, 0.1,
1.0, 2.5, 5.0, and 10 ng/ml), and it was shown that the
best results were obtained with the highest concentra-
tion used (10 ng/ml, data not shown) which is in accord-
ance to the optimal concentrations for the expression of
genes of interest in the description of this system [17].
In vitro invasiveness assay in caco-2 cells and BMDCs
The recombinant strains LL-FnBPA and LL-pNisFnBPA
were co-incubated with Caco2 cells or bone marrow de-
rived dendritic cells (BMDCs), as well as two control
L. lactis wild type strains (LL-NZ9000 and LL-MG1363).
The bacterial invasiveness was then defined by the ratio
between internalized bacteria, determined by colony
forming units observed after cell lysis and plating, and
bacteria input for co-incubation. Figure 2 shows the in-
vasiveness levels obtained with the four L. lactis strains
using Caco-2 and BMDC cellular models, respectively.
In the Caco-2 cell model, it can be noted, that the inva-
sive LL-FnBPA strain allows greater invasiveness levels
(between 3 and 6 times) than the control strains. This
invasiveness value can even reach a 10 fold increase in
the case of BMDCs model. Moreover, in both cellular
models, the LL-pNisFnBPA strain exhibits invasiveness
levels 3 to 4 times greater than the LL-FnBPA strain.
Therefore, the increase of FnBPA expression on the out-
side bacterial membrane can be related to an improved
internalization ability in eukaryote cells in vitro.
In vivo invasiveness assay in the intestinal tract of mice
In an attempt to compare the DNA transfer properties
in vivo of LL-FnBPA and LL-pNisFnBPA, the pValac plas-
mid containing the gfp gene [7] was used to transform
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Figure 2 In vitro invasiveness assays of LL-NZ9000, LL-MG1363,
LL-FnBPA and LL-PnisA-FnBPA strains in A) Caco-2 cells and B)
BMDCs. Results are expressed as means ± standard deviation.
a-cMeans with a different letter are significantly different from
each other with a p ≤ 0.05.
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GFP and LL-pNisFnBPA-GFP, respectively.
The subsequent oral administration of mice with
LL-pOri23-GFP, LL-FnBPA-GFP or LL-pNisFnBPA-GFP
allowed us to evaluate the effect of FnBPA expression on
DNA delivery as observed by the presence of fluorescence
(GFP expression by pValac:GFP) in the small and large
intestine tissues, 24 hours after administration.
The importance of FnBPA in the DNA delivery was
observed mainly in large intestine. Mice that received
LL-FnBPA-GFP showed significant increases (P < 0.05)
in the number of fluorescent cells compared to the mice
that received LL-pOri23-GFP (Figure 3). The improvement
of the delivery system with the addition of the promoter
pNisA to increase the expression of FnBPA was also
demonstrated. Mice that received LL-pNisFnBPA-GFP
strain showed the highest number of GFP positive cells in
both small and large intestines (Figure 3); however, when
comparing this strain with LL-FnBPA-GFP, a significant
higher number of fluorescent cells was (P < 0.05) only
observed in the large intestine (Figure 3).
Fluorescent cell counts are in favor of a more efficient
DNA transfer associated with the LL-pNisFnBPA-GFP
strain, where the FnBPA gene is under the control of
the nisA promoter, compared with the native promoterLL-FnBPA-GFP strain, and the control LL-pOri23-GFP
strain without FnBPA.
Discussion
In this study, the design of a particular Lactococcus lactis
strain expressing FnBPA on the external membrane
under the control of the strong inducible nisA promoter
was described. This so-called LL-pNisFnBPA strain was
studied for its properties to improve DNA delivery
in vitro on eukaryote cell models, as well as in vivo in
mice intestinal tract. This recombinant strain was ob-
tained from the transformation of the wild type L. lactis
NZ9000 strain, since it contains the nisR and nisK genes
which are needed for the regulation of the expression
system based on the nisA promoter [18,19].
A sub-inhibitory nisin concentration (10 ng/ml) was
used for the overnight induction of the LL-pNisFnBPA-
GFP strain allowing then a 55% gain regarding FnBPA
expression compared with LL-FnBPA where FnBPA pro-
duction is under the control of its constitutive promoter.
This shift is in agreement with the nisA promoter strength
already described where the efficiency of the nisA pro-
moter is compared to other promoter in Gram-positive
bacteria [17].
It is now well established that LL-FnBPA recombinant
strains exhibit good properties of internalization in Caco-2
cells as can be observed by GFP expression plasmid deliv-
ery [20] or through the expression of BLG in vivo [21].
Here, we confirmed this capacity in vitro on Caco-2
cells and showed in addition that an enhancement of
FnBPA expression, by the use of LL-pNisFnBPA strain, re-
sulted in an increase of invasiveness level of 4 to 5 times
compared to the LL-FnBPA strain.
Moreover, we showed for the first time that FnBPA
production at the surface of LAB increase invasiveness
in BMDCS. Both strains LL-FnBPA and LL-pNisFnBPA
showed higher invasiveness in BMDCs than in Caco-2
cells compared to non-invasive LL strain. This observation
can come close to the fact that pathogenic bacteria uptake
by dendritic cells also involves the DC maturation stage
independently of the invasin [22]. The increase of FnBPA
expression is directly related to the higher invasiveness
level associated to the LL-pNisFnBPA strain when co-
incubated with Caco2 cells or BMDCs.
An in vivo study was also performed (Figure 3) using
the pValac delivery system with GFP being used as the
indicator of DNA delivery and expression. The effective-
ness of this DNA delivery system was demonstrated pre-
viously in healthy mice that received LL-FnBPA-GFP
[21] and also in a TNBS-induced colitis mouse model,
where the delivery of IL-10 DNA was evaluated using
LL-FnBPA-IL10 [23]. In both animal models, the recom-
binant L. lactis strain expressed FnBPA under its own
constitutive promoter. Here, it was observed that the
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the DNA delivery in the intestinal tract of mice that re-
ceived LL-pNisFnBPA-GFP, compared to the mice that
received LL-FnBPA-GFP.
The transit of L. lactis in the digestive tract has been
especially described [24]. It turns out that L. lactis does
not colonize the gastrointestinal tract and exhibits a lowsurvival in the gut. As a matter of fact, if L. lactis is re-
sistant to gastric acidity it can be noted that less than
one third of the orally administrated bacteria survive in
the duodenum. So, the expression of FnBPA can help to
the DNA delivery by this LAB. This was confirmed in the
present work where we detected increased DNA trans-
fer in the cells of small intestine, and even more in the
Almeida et al. BMC Microbiology 2014, 14:248 Page 5 of 8
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recombinant L. lactis strains that expressed FnBPA
(LL-pNisFnBPA-GFP and LL-FnBPA-GFP), compared to
the animals that received L. lactis without the fnbpa gene
(LL-pOri23-GFP). It is also important to note that DNA
delivery in the intestine was increased by the use of pNisA
promoter in the recombinant strain as a replacement to
the constitutive promoter used in other studies.
The animal model used in the present work did not
show any adverse secondary effect in the mice that re-
ceived the recombinant strains; however, considering
that this experiment consisted in only 24 h, new experi-
ments to evaluate the safety of this new recombinant
strain are currently under way using healthy animals
and also animals with some specific intestinal path-
ologies such as induced Crohn’s disease and colon cancer
models.
Conclusion
One of the immunotherapy research fields is looking
for adapted bacterial vectors as DNA vaccine carriers
[25-27]. In this report, we describe the design of a L. lactis
recombinant strain where the expression of FnBPA, the
invasin from S. aureus, is driven by the nisA promoter.
We showed that this L. lactis strain provides an improved
tool for bacterial invasiveness and DNA transfer as can be
observed by co-incubation with Caco2 cells or BMDCs,
as well as by GFP expression in small and large intes-
tine after orally administration of recombinant strains
that expressed pValac:gfp.
Therefore, these results highly suggest that the en-
hancement of FnBPA expression on the bacterial mem-
brane through the engineering of a promoter system is
directly correlated to the increase of DNA delivery prop-
erties, which is a good illustration of the knowledgeTable 1 Strains and plasmids used in this work along with th
growth and references
Host strain Denomination Plasmids
NZ 9000 LL-NZ9000 No plasmid
MG1363 LL-FnBPA pOri23 FnBPA
NZ9000 LL-pSEC-E7 pSEC-E7
NZ9000 LL-pNisFnBPA pNis A - pOri253 FnBP
NZ9000 LL-pNisFnBPA-GFP pNis A - pOri253 FnBP
pValac:GFP
MG1363 LL-FnBPA-GFP pOri23 FnBPA
pValac-GFP
MG1363 LL-pOri23-GFP pOri23
pValac-GFP
MG1363 LL-MG1363 No plasmidacquired in the field of DNA vaccine or the production
of other beneficial proteins.
Methods
Cloning and plasmid construction
The pSEC-E7 plasmid containing the nisA gene pro-
moter was used to provide the corresponding fragment
by digestion with BamHI and BglII enzymes. In addition
the BamHI FnBPA gene fragment, without its constitu-
tive promoter, was recovered by a BamHI digestion of a
pORI23 plasmid containing the FnBPA gene (Table 1).
This FnBPA fragment was then inserted in the pORI253
plasmid linearized with Ecl136II. The resulting construc-
tion was subsequently linearized by SalI digestion for
the insertion of the nisA promoter upstream FnBPA to
produce the Pnis-FnBPA plasmid. The cloning region
was sequenced after each stage of the construction for
orientation control.
Cells
Human colon carcinoma cell line (Caco-2, ATCC), were
routinely grown in 25 cm2 plastic flask (Costar) in DMEM,
10% SBF, 2 mM L-glutamine, 0.1 mg/L streptomycin,
100.000 U/L penicillin and 1 mM sodium pyruvate. Cells
were kept at 37°C in 5% CO2, 90-95% humidity, trypsinized
weekly (0.25% trypsin, 5 mM EDTA in Ca-Mg-Free Hanks’
balanced salt) and seeded onto new flask (1/10, v/v). Mur-
ine bone marrow dendritic cells (BMDCs) were generated
from bone marrow (BM) progenitor cells isolated from fe-
murs and tibias of BALB/c mice as previously described
[30], with minor modifications. Briefly, after red cell lysis
(ammonium chloride 0.14 M, pH 7.2), BM cells were cul-
tured in Petri dishes at 2 × 105 cells/mL in complete
Iscove’s Modified Dulbecco’s Medium (IMDM, Sigma,
St. Louis, USA) supplemented with 10% (v/v) heat-inactivatedeir denomination in this work, mediums used for their
Medium and antibiotics References
M17 + 0.5% Glucose [19]
M17 + 0.5% Glucose, Ery R [16]
M17 + 0.5% Glucose, Cm R [28]
A M17 + 0.5% Glucose, Ery R This work
A M17 + 0.5% Glucose, Ery R and Cm R This work
M17 + 0.5% Glucose, Ery R and Cm R [20]
M17 + 0.5% Glucose, Ery R and Cm R This work
M17 + 0.5% Glucose [29]
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2-mercaptoethanol, 1 mM glutamine, 50 μg/mL genta-
mycin and 20 ng/mL of recombinant mouse GM-CSF.
Freshly prepared medium was added every three days and
BMDCs were used on day 11 of culture (maximum of
CD11c expression as checked by FACS analysis).
Bacterial strains
L. lactis strains were cultured in M17 medium containing
0.5% glucose (GM17) at 30°C without shaking. Plasmids
containing pNisA-FnBPA genes were transferred to L. lactis
NZ 9000 by electroporation as previously described [31,32].
After preliminary tests, pValac-GFP plasmids were also in-
troduced in L. lactis containing pNisA-FnBPA by the same
way. Antibiotics were added at the indicated concentrations
as necessary (erythromycin 5 μg/mL, chloramphenicol
10 μg/mL). Strains and plasmids used in this work are listed
in Table 1.
FnBPA induction and protein measurement
All experiment with the strain containing the fnbpA gene
under the control of pNisA was performed using nisin
(10 ng/mL; Sigma) as previously described [33] with some
modifications. Briefly, overnight cultures in GM17 medium
were diluted 1:20 and bacteria were grown until they
reached an OD600 = 0.5, then nisin was added and bacteria
grew for another 16 hours. To compare FnBPA levels, each
strain was washed and resuspended in PBS, 1 × 105 CFU
were incubated with 500 μL of primary antibody (1/1000
anti-FnBPA α produced in rabbit [20] for 1 hour at 4°C.
Pellet was washed with phosphate buffered saline (PBS) so-
lution 0.01 M, pH 7.4 and the secondary antibody was
added (1/100 - FITC conjugated affinity pure Fab fragment
goat anti-rabbit IgG (H + L)) followed by incubation at 4°C
during 1 hour. Samples were washed again and analyzed
by flow cytometry (BD Accuri™ Flow Cytometer). Data
were analyzed using CFlow Plus software.
In vitro invasiveness assays of FnBPA strains in caco-2 and
BMDCs
In vitro invasiveness assays were performed as previously
described [5,7,34] using the human colon carcinoma cell
line (Caco-2) or murine bone marrow dendritic cells
(BMDCs). Cells were cultured as described above, and dis-
tributed in P12 dishes (4 × 105 cells per well), bacteria were
added to mammalian cells with a multiplicity of infection
(MOI) of 103 bacteria per cell in medium without antibi-
otics. After two hours of co-incubation, cells were carefully
washed three times with PBS and treated with gentamicin
(150 μg/mL) for two hours in order to kill extracellular
bacteria. Cells were washed again and disrupted (sterile
PBS 1X + 0.2% triton, 4°C during 10 minutes), colony
forming units (CFU) were counted after plating serial dilu-
tions of these cells. All experiments were done in triplicate.GFP detection in cells from the small and large intestines
of mice
Bacterial strains were grown and prepared as described
above with 10 ng/ml of nisin for induction in all strains
(which is a sub inhibitory concentration but induces
expression in the pNisFnBPA containing strain). LL-FnBPA
was used as control without GFP; LL-pOri23-GFP and
LL-FnBPA-GFP were used to evaluate the possible benefit
in DNA delivery related to FnBPA expression, and
LL-pNisFnBPA-GFP was used to examine the effect in
DNA delivery related to increased bacterial invasiveness.
Six-week-old female BALB/c mice weighing 20–25 g were
obtained from the inbred closed colony maintained at
CERELA (Centro de Referencia para Lactobacilos, San
Miguel de Tucumán, Argentina). Three mice per group
were fed by gavage with each bacterial suspension
(108UFC/mouse) orally using a gavage syringe. After 24 h
of administration, mice were sacrificed by cervical disloca-
tion and small and large intestines were removed, washed
with PBS and prepared for histological evaluation using
standard techniques. Serial paraffin sections (4 μm) were
made and after deparaffinization were mounted in glycerol/
PBS (9/1) solution and observed using a fluorescence light
microscope. The number of fluorescent cells was counted
by two different researchers (two individual blind counts
per sample) and the results were expressed as the mean
number of positive cells counted in ten fields of vision as
seen at 1000 ×magnification.
Statistical analysis
Fluorescent intensity was analyzed using data from Accuri –
CFlow Plus and GraphPad Prism 5.00 (Unpaired t test).
Invasiveness assays were also analyzed by means of and
GraphPad Prism 5.00 using Bonferroni’s Multiple Com-
parison Test.
For animal trials, the test and control groups contained
3 animals and the experimental protocol was performed
two times (no interactions between these two trials were
observed) and all the results (from the two trials) were an-
alyzed together (N = 6).
Statistical analyses were performed using MINITAB 15
software. Comparisons were accomplished by an ANOVA
general linear model followed by a Tukey’s post hoc test.
Ethics statement
The Animal Protection Committee of CERELA preap-
proved all animal protocols and all experiments complied
with the current laws of Argentina.
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